| 一、持续督导工作情况 | | --- | | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 的持续督导工作制定相应的工作计划 | 保荐机构已建立健全并有效执 | | | 建立健全并有效执行持续督导工作制度，并针对具体 | 行了持续督导制度，并制定了 | | | | 相应的工作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始前， | 保荐机构已与诺诚健华签订 | | | 与上市公司或相关当事人签署持续督导协议，明确双 | 《保荐协议》及《持续督导协 | | | 方在持续督导期间的权利义务，并报上海证券交易所 | 议》，该协议明确了双方在持 | | | 备案 | 续督导期间的权利和义务，并 | | | | 报上海证券交易所备案 | | 3 | 持续督导期间，按照有关规定对上市公司违法违规事 | 2023年1-6月诺诚健华在持续督 | | | 项公开发表声明的，应于披露前向上海证券交易所报 | 导期间未发生按有关规定需保 | | | | 荐机构公开发表声明的违法违 | | | 告，并经上海证券交易所审核后在指定媒体上公告 | 规情况 | | | 持 ...

| A | 股代码：688428 | A | 股简称：诺诚健华 | 公告编号：2023-024 | | --- | --- | --- | --- | --- | | 港股代码：09969 | 港股简称：诺诚健华 | | | | 诺诚健华医药有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 30 日(星期三)上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 23 日(星期三)至 8 月 29 日(星期二)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 IR@innocarepharma.com 进行提问。公司将在说明会上对投资者普遍关 ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問，應咨詢股票經紀或其他註冊證券交易商、銀行經 理、律師、專業會計師或其他專業顧問。 閣下如已將名下所有諾誠健華醫藥有限公司的股份出售或轉讓，應立即將本通函交予買主或承讓人或經手 買賣的銀行、股票經紀或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不就本通函全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9969） (1)建議採納二零二三年股權激勵計劃；及 (2)股東特別大會通告 諾誠健華醫藥有限公司謹訂於二零二三年八月三十一日（星期四）上午十時正假座中國北京市昌平區中 關村生命科學園生命園路8號院8號樓舉行股東特別大會，大會通告載於本通函第EGM-1至EGM-3頁。 隨函亦附上股東特別大會適用的代表委任表格。代表委任表格亦將於香港聯合交易所有限公司網站 ( www.hkexnews.hk)及本 ...

关于召开 2023 年第一次临时股东大会（股东特别大 会）的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年第一次临时股东大会（股东特别大会） 召开日期时间：2023 年 8 月 31 日 10 点 00 分 网络投票系统：上海证券交易所股东大会网络投票系统 | A 股代码：688428 | A 股简称：诺诚健华 公告编号：2023-023 | | --- | --- | | 港股代码：09969 | 港股简称：诺诚健华 | 诺诚健华医药有限公司 （七） 涉及公开征集股东投票权 网络投票起止时间：自 2023 年 8 月 31 日 股东大会召开日期：2023年8月31日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开地点：北京市昌平区中关村生命科学园生命园路 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 香港，2023年8月14日 InnoCare Pharma Limited 諾誠健華醫藥有限公司 (於開曼群島註冊成立的有限公司) (股份代號：9969) 董事會召開日期 諾誠健華醫藥有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 2023年8月29日（星期二）舉行董事會會議，藉以（其中包括）考慮並批准本公司及 其附屬公司截至2023年6月30日止六個月中期業績及其發佈。 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士； 非執行董事施一公博士、謝榕剛先生及金明先生；以及獨立非執行董事胡蘭女士 及陳凱先博士。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 為確定股東出席股東特別大會並於會上投票的資格，本公司將由二零二三年八月 二十八日（星期一）至二零二三年八月三十一日（星期四）（首尾兩日包括在內）暫 停辦理股份過戶登記手續，期間將不會辦理任何股份的過戶登記。 為符合資格出席股東特別大會並於會上投票，所有股份過戶文件連同有關股票最 遲須於二零二三年八月二十五日（星期五）下午四時三十分前送達本公司的證券過 戶登記處香港中央證券登記有限公司的辦事處（地址為香港灣仔皇后大道東183號 合和中心17樓1712-1716號舖）以作登記。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9969） 暫停辦理股份過戶登記手續 諾誠健華醫藥有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公 司將於二零二三年八月三十一日（星期四）舉行特別大會（「股東特別大會」），以供 本公司股東（「股東」 ...

Financial Performance - The company's revenue for Q1 2023 was RMB 189,387,628.40, representing a year-on-year increase of 58.99%[4] - Pharmaceutical sales revenue reached RMB 151,370,102.78, an increase of 43.46% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of RMB 12,406,466.71, with a year-on-year decrease of 89.51%[4][8] - Total revenue for Q1 2023 was RMB 189.39 million, a 59% increase from RMB 119.12 million in Q1 2022[19] - Net profit for Q1 2023 was a loss of RMB 14.23 million, significantly improved from a loss of RMB 120.62 million in Q1 2022[20] - Comprehensive income for Q1 2023 was a loss of RMB 100.50 million, compared to a loss of RMB 141.11 million in Q1 2022[21] Cash Flow and Liquidity - The net cash flow from operating activities was negative at RMB -153,933,775.03[4] - Operating cash inflow totaled $187.54 million, up from $139.50 million year-over-year[23] - Cash outflow from operating activities reached $341.47 million, compared to $277.49 million in the previous year[23] - Net cash flow from operating activities was -$153.93 million, worsening from -$137.99 million year-over-year[23] - Cash inflow from investment activities was $41.31 million, down from $55.79 million in the previous year[23] - Cash outflow from investment activities amounted to $43.22 million, significantly lower than $1.67 billion in the previous year[23] - Net cash flow from investment activities was -$1.92 million, compared to -$1.61 billion year-over-year[23] - Cash flow from financing activities resulted in a net outflow of -$9.03 million, compared to -$8.51 million in the previous year[25] - The ending balance of cash and cash equivalents was $3.99 billion, down from $1.47 billion year-over-year[25] Research and Development - R&D expenses totaled RMB 140,950,687.03, accounting for 74.42% of revenue, a decrease of 34.20 percentage points year-on-year[5][8] - R&D expenses increased to RMB 140.95 million, up from RMB 129.40 million, reflecting a growth of about 8.5%[19] Assets and Liabilities - Total assets at the end of the reporting period were RMB 10,215,914,005.30, a decrease of 1.09% from the end of the previous year[5] - The total assets of the company decreased to approximately ¥10.22 billion from ¥10.33 billion, a decline of about 1.1%[18] - Total liabilities decreased slightly to approximately ¥2.65 billion from ¥2.68 billion, a reduction of about 1.4%[17] - The company reported a total equity of approximately ¥7.57 billion, down from ¥7.64 billion, indicating a decrease of about 1.1%[18] - The company’s total current liabilities amounted to approximately ¥2.04 billion, a slight decrease from ¥2.07 billion, reflecting a reduction of about 1.6%[17] Shareholder Information - The company had a total of 23,135 common shareholders at the end of the reporting period[9] - HKSCC NOMINEES LIMITED held 41.13% of the shares, making it the largest shareholder[10] Other Income and Expenses - The company reported a government subsidy of RMB 11,137,224.44 included in non-recurring gains and losses[6] - Other income decreased to RMB 11.14 million from RMB 21.40 million, a decline of approximately 48.2%[19] - Investment loss improved to RMB -0.71 million from RMB -3.16 million, indicating a positive trend[20] - The company reported a foreign exchange loss of RMB -6.46 million, compared to a loss of RMB -5.55 million in the previous year[20] Employee Compensation - The company reported a significant increase in cash paid to employees, totaling $146.72 million, compared to $117.42 million in the previous year[23]

2022 年年度报告 公司代码：688428 公司简称：诺诚健华 诺诚健华医药有限公司 2022 年年度报告 1 / 252 2022 年年度报告 重要提示 一、 本公司董事会、及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 √是 □否 公司是一家以卓越的自主研发能力为核心驱动力的高科技创新生物医药企业，拥有全面的研 发、生产和商业化能力，专注于肿瘤和自身免疫性疾病等存在巨大未满足临床需求的领域，在全 球市场内开发具有突破性潜力的同类首创或同类最佳药物。2022 年度，公司实现净利润-8.94 亿 元，剔除非现金部分（未实现汇兑损益及股权激励费用）后为-4.74 亿元。这主要由于新药研发、 生产、商业化是一个周期长、投资大、风险高的过程，公司在药物早期发现、临床前研究、临床 开发、注册、生产、商业化推广等多个环节持续投入。报告期内，公司持续加大在新技术平台建 设，临床前研究及临床试验方面的投入，研发费用为 6.49 亿元，扣除一次性授权引入费用后，与 上年同期相比增长 28.05%。 随着 ...

| A 股代码：688428 | A 股简称：诺诚健华 | 公告编号：2023-007 | | --- | --- | --- | | 港股代码：09969 | 港股简称：诺诚健华-B | | 诺诚健华医药有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 4 月 27 日(星期四)上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （一）会议召开时间：2023 年 4 月 27 日上午 11:00-12:00 （二） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心网络互动 三、 参加人员 投资者可于 2023 年 4 月 2 ...

Financial Performance - In Q3 2022, the sales revenue of Orelabrutinib (Yinokai®) reached RMB 183 million, a 64% increase compared to Q2 2022, and a 129% increase year-on-year for the first nine months of 2022, totaling RMB 400 million[4]. - The total operating revenue for Q3 2022 was RMB 196 million, a decrease of 77.76% year-on-year, primarily due to a strategic cooperation agreement with BeiGene in Q3 2021 that generated RMB 776 million in licensing revenue[5]. - The net loss attributable to shareholders for Q3 2022 was RMB 393 million, representing a 232.11% increase compared to the same period last year[7]. - Revenue for the current reporting period decreased by 77.76% compared to the same period last year, primarily due to a high one-time technology licensing income recognized in the previous year[11]. - Net profit attributable to shareholders decreased by 232.11% in the current reporting period, influenced by the high technology licensing income recognized in the previous year[11]. - Total operating revenue for the first three quarters of 2022 was CNY 441.61 million, a significant decrease from CNY 981.43 million in the same period of 2021[24]. - Net profit for the first three quarters of 2022 was a loss of CNY 842.65 million, compared to a profit of CNY 87.31 million in the same period of 2021[25]. - Basic and diluted earnings per share for the third quarter of 2022 were both CNY -0.59, compared to CNY 0.06 in the same quarter of 2021[26]. Research and Development - Research and development expenses for the first nine months of 2022 amounted to RMB 475 million, reflecting a 30% increase after excluding the previous year's upfront payment to Incyte Corporation[5]. - The R&D expenses accounted for 100.71% of operating revenue in Q3 2022, reflecting a 55.14 percentage point increase compared to the same period last year[7]. - R&D investment decreased by 50.85% in the current reporting period, mainly due to last year's payment related to Incyte[13]. - The proportion of R&D investment to operating revenue increased by 55.14 percentage points in the current reporting period, reflecting the company's increased focus on R&D[13]. - The company has 13 products in various stages of clinical trials, with several others in preclinical stages, indicating a robust pipeline for future growth[4]. Assets and Liabilities - The company's total assets as of September 30, 2022, were RMB 10.43 billion, a 40.68% increase year-on-year[7]. - Total assets increased by 40.68% year-to-date, primarily due to the increase in funds raised from the A-share listing[13]. - The company's equity attributable to shareholders reached CNY 7,736,172,992.15, up from CNY 5,604,559,524.19, representing an increase of about 37.9%[22]. - Total liabilities increased to CNY 2,649,251,273.58 from CNY 1,756,050,524.82, which is an increase of approximately 50.7%[22]. Cash Flow and Liquidity - As of September 30, 2022, the company held cash and cash equivalents exceeding RMB 9.2 billion, with net cash exceeding RMB 7.7 billion, ensuring sufficient liquidity for ongoing projects[5]. - The net cash flow from operating activities decreased by 241.19% year-to-date, attributed to high one-time technology licensing payments received in the previous year and increased personnel costs due to a rise in R&D and production staff[11]. - Cash flow from operating activities showed a net outflow of CNY 395.32 million in 2022, contrasting with a net inflow of CNY 279.98 million in 2021[27]. - The net increase in cash and cash equivalents was 1,176,888,160.90 CNY, down from 2,133,772,073.22 CNY, indicating a decrease in overall liquidity growth[28]. - Cash inflow from investments totaled 2,789,411,528.74 CNY, an increase from 2,526,674,475.99 CNY, suggesting enhanced investment attraction[28]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 118,973[15]. - The company issued a total of 1,764,321,452 shares, with 85% listed in Hong Kong and 15% on the Shanghai Stock Exchange[14]. - The top ten shareholders hold a combined 88.10% of the company's shares, with HKSCC NOMINEES LIMITED holding 41.07%[16]. - The number of shares held by the top ten shareholders includes significant stakes from HKSCC NOMINEES LIMITED with 724,573,837 shares and HHLR Fund, L.P. with 208,671,222 shares[18]. Strategic Focus - The company continues to focus on expanding its market presence and developing innovative therapies for unmet clinical needs in oncology and autoimmune diseases[4]. - The company plans to focus on market expansion and new product development to improve future performance[24]. - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[19]. Financial Management - The company incurred financial expenses of CNY 311.95 million, compared to a financial income of CNY 98.51 million in the previous year[24]. - Total cash inflow from financing activities reached 3,129,667,311.83 CNY, up from 2,526,674,475.99 CNY, reflecting a strong increase in financing efforts[28]. - Net cash flow from financing activities was 3,106,021,468.26 CNY, compared to 2,505,380,367.38 CNY in the previous period, showing improved financial management[28]. Other Financial Metrics - The company reported a significant increase in sales expenses, which rose to CNY 290.26 million from CNY 187.45 million year-over-year[24]. - Other comprehensive income after tax for the first three quarters of 2022 was CNY 563.17 million, compared to a loss of CNY 2.96 million in the same period of 2021[25]. - Investment activities generated cash inflow of CNY 144.46 million in 2022, a sharp decline from CNY 2.12 billion in 2021[27]. - The company has adopted new accounting standards starting from 2022, which may affect financial reporting and analysis[29].